369 related articles for article (PubMed ID: 22643564)
1. Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma.
Zafar SF; El-Rayes BF
Am J Clin Oncol; 2014 Apr; 37(2):194-200. PubMed ID: 22643564
[TBL] [Abstract][Full Text] [Related]
2. Metastatic pancreatic cancer response to treatment with cetuximab and gemcitabine plus capecitabine: a case report and review of the literature.
Li M; Jiang M; Yan X; Wang F; Luo F
Tumori; 2010; 96(5):764-7. PubMed ID: 21302625
[TBL] [Abstract][Full Text] [Related]
3. New directions in the management of advanced pancreatic cancer: a review.
Rocha-Lima CM
Anticancer Drugs; 2008 Jun; 19(5):435-46. PubMed ID: 18418211
[TBL] [Abstract][Full Text] [Related]
4. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
[TBL] [Abstract][Full Text] [Related]
5. Palliative chemotherapy for pancreatic malignancies.
Mehta SP
Surg Clin North Am; 2010 Apr; 90(2):365-75. PubMed ID: 20362792
[TBL] [Abstract][Full Text] [Related]
6. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
De Jesus-Acosta A; Oliver GR; Blackford A; Kinsman K; Flores EI; Wilfong LS; Zheng L; Donehower RC; Cosgrove D; Laheru D; Le DT; Chung K; Diaz LA
Cancer Chemother Pharmacol; 2012 Feb; 69(2):415-24. PubMed ID: 21800112
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
[TBL] [Abstract][Full Text] [Related]
8. Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma.
Ajouz H; Mukherji D; Haydar A; Yakan AS; Saleh A; Elias E; Temraz S; Faraj W; Khalife M; Shamseddine A
J Gastrointest Cancer; 2014 Mar; 45(1):109-12. PubMed ID: 24362621
[TBL] [Abstract][Full Text] [Related]
9. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
Ko AH; Youssoufian H; Gurtler J; Dicke K; Kayaleh O; Lenz HJ; Keaton M; Katz T; Ballal S; Rowinsky EK
Invest New Drugs; 2012 Aug; 30(4):1597-606. PubMed ID: 21629990
[TBL] [Abstract][Full Text] [Related]
10. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.
Philip PA; Benedetti J; Corless CL; Wong R; O'Reilly EM; Flynn PJ; Rowland KM; Atkins JN; Mirtsching BC; Rivkin SE; Khorana AA; Goldman B; Fenoglio-Preiser CM; Abbruzzese JL; Blanke CD
J Clin Oncol; 2010 Aug; 28(22):3605-10. PubMed ID: 20606093
[TBL] [Abstract][Full Text] [Related]
11. Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer.
Bayoglu IV; Varol U; Yildiz I; Muslu U; Alacacioglu A; Kucukzeybek Y; Akyol M; Demir L; Dirican A; Cokmert S; Yildiz Y; Karabulut B; Uslu R; Tarhan MO
Asian Pac J Cancer Prev; 2014; 15(17):7119-23. PubMed ID: 25227800
[TBL] [Abstract][Full Text] [Related]
12. Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
Hess V; Pratsch S; Potthast S; Lee L; Winterhalder R; Widmer L; Cescato C; Lohri A; Jost L; Stillhart P; Pestalozzi B; Herrmann R
Ann Oncol; 2010 Dec; 21(12):2390-2395. PubMed ID: 20444846
[TBL] [Abstract][Full Text] [Related]
13. [Salvage chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer: survival benefit in selected patients].
Lee JL; Kim YT
Korean J Gastroenterol; 2008 Jul; 52(1):59-63. PubMed ID: 19077495
[No Abstract] [Full Text] [Related]
14. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen.
Reni M; Cereda S; Galli L
Cancer Lett; 2007 Oct; 256(1):25-8. PubMed ID: 17561341
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Kulke MH; Blaszkowsky LS; Ryan DP; Clark JW; Meyerhardt JA; Zhu AX; Enzinger PC; Kwak EL; Muzikansky A; Lawrence C; Fuchs CS
J Clin Oncol; 2007 Oct; 25(30):4787-92. PubMed ID: 17947726
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Saif MW; Syrigos K; Penney R; Kaley K
Anticancer Res; 2010 Jul; 30(7):2905-9. PubMed ID: 20683031
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
Hill ME; Li X; Kim S; Campbell A; Culler K; Bloomston M; Zalupski M; Hejna G; Bekaii-Saab T
Cancer Chemother Pharmacol; 2011 Mar; 67(3):511-7. PubMed ID: 20461379
[TBL] [Abstract][Full Text] [Related]
18. Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network.
Cartwright T; Richards DA; Boehm KA
Cancer Control; 2008 Oct; 15(4):308-13. PubMed ID: 18813198
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic cancer: an update.
Kindler HL
Curr Oncol Rep; 2007 May; 9(3):170-6. PubMed ID: 17430687
[TBL] [Abstract][Full Text] [Related]
20. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Li J; Saif MW
JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
